GO:0004661 protein geranylgeranyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004661 (protein geranylgeranyltransferase activity) catalyzes the covalent attachment of a 20-carbon geranylgeranyl isoprenoid group to a cysteine residue near the C-terminus of target proteins via a thioether linkage.
• The enzyme is best known as geranylgeranyltransferase type I (GGTase-I), a heterodimeric zinc metalloenzyme that modifies Rho-family GTPases such as RHOA, RAC1 and CDC42.
• GGTase-I activity is essential for membrane anchoring and signaling of Rho GTPases, and its inhibition is actively pursued as an anti-cancer and anti-inflammatory strategy.
• Loss of GGTase-I function causes unprenylated RHO GTPase signaling that can drive pyrin inflammasome-dependent erosive arthritis, linking the enzyme to autoinflammatory disease.
• In the brain, GGTase-I-mediated prenylation regulates neuronal survival, synaptic function and neurodegeneration-related pathways.
• CRISPR knockout, point-mutation, knock-in and overexpression models are key tools for dissecting GGTase-I substrate specificity and disease relevance.
Description
Protein geranylgeranyltransferase activity (GO:0004661) is a molecular function that covalently attaches a 20-carbon geranylgeranyl isoprenoid group to a cysteine residue at or near the C-terminus of a substrate protein through a thioether bond. This post-translational modification, called geranylgeranylation, increases the hydrophobicity of the target protein and promotes its association with cellular membranes, which is critical for the biological activity of many small GTPases. The best-characterized enzyme carrying this activity is protein geranylgeranyltransferase type I (GGTase-I), a heterodimeric zinc metalloenzyme that recognizes a C-terminal CaaX motif in substrate proteins. Because geranylgeranylation controls the localization and signaling of Rho-family GTPases such as RHOA, RAC1 and CDC42, the activity of GGTase-I influences diverse processes including cytoskeletal dynamics, cell proliferation, inflammation and neuronal function. Dysregulated geranylgeranylation has been implicated in cancer, autoinflammatory syndromes and neurodegenerative conditions, making GO:0004661 an attractive target for pharmacological and genetic interrogation. For researchers, GO:0004661 provides a precise functional annotation for experiments involving prenylation assays, GGTase-I inhibitors, and CRISPR-based perturbation of GGTase-I subunits or their substrates. Understanding this activity at the structural, cellular and organismal level is therefore essential for both basic cell biology and translational drug discovery.
protein geranylgeranyltransferase activity At A Glance
| GO ID | GO:0004661 |
|---|---|
| GO term | protein geranylgeranyltransferase activity |
| Ontology | molecular_function |
| Synonym | protein-cysteine geranylgeranyltransferase activity |
| Major function | Covalent transfer of a 20-carbon geranylgeranyl group to a C-terminal cysteine of target proteins |
| Representative enzyme | Geranylgeranyltransferase type I (GGTase-I), a heterodimeric zinc metalloenzyme |
| Isoprenoid donor | Geranylgeranyl diphosphate (GGPP) |
| Substrate motif | C-terminal CaaX box, typically ending in leucine |
| Metal requirement | Zinc-dependent catalysis |
What Is GO:0004661?
GO:0004661, protein geranylgeranyltransferase activity, is defined as the catalysis of the covalent addition of a geranylgeranyl (20-carbon isoprenoid) group via thioether linkages to a cysteine residue at or near the C terminus of a protein. In practice, this activity is executed by geranylgeranyltransferase enzymes that use geranylgeranyl diphosphate as the isoprenoid donor and a CaaX-motif cysteine in the acceptor protein as the nucleophile.
Why Is protein geranylgeranyltransferase activity Important in Cell Biology?
Protein geranylgeranyltransferase activity is important because it governs the membrane targeting and function of a large set of signaling proteins, most notably Rho-family GTPases, and thereby influences cell growth, cytoskeletal organization, inflammation and neuronal survival. Pharmacological inhibition of GGTase-I has shown anti-tumor activity in preclinical models, and genetic loss of GGTase-I function causes unprenylated RHO GTPase signaling that drives pyrin inflammasome-dependent erosive arthritis. These findings establish GO:0004661 as a central node linking prenylation biochemistry to human disease and as a validated target for experimental therapeutics.
• Controls membrane localization and signaling of Rho-family GTPases such as RHOA, RAC1 and CDC42.
• GGTase-I inhibitors show potent anti-tumor activity by blocking Rho-GTPase signaling.
• Selective GGTase-I inhibitors have been developed with high potency and cellular activity.
• Loss of GGTase-I function causes pyrin inflammasome-driven erosive arthritis in vivo.
• GGTase-I-mediated prenylation is important for brain function and neurodegeneration-related pathways.
• The enzyme is a zinc metalloenzyme, and metal ions influence substrate binding and catalysis.
• Geranylgeranylation is a validated target in cancer drug discovery.
• Allenoate-derived compounds can inhibit both GGTase-I and Rab GGTase, providing chemical probes.
• Prenyltransferase structure-function studies inform rational inhibitor design.
• CRISPR models of GGTase-I subunits enable causal testing of prenylation in disease.
Molecular Mechanism of protein geranylgeranyltransferase activity
Substrate recognition and CaaX motif binding
In simple terms: The enzyme first grabs the target protein by its C-terminal CaaX tag.
GGTase-I recognizes substrate proteins through a C-terminal CaaX motif, where the cysteine is the site of modification and the terminal residue is typically leucine. This motif-based recognition ensures that only proteins ending in the appropriate sequence are geranylgeranylated. Metal ions, particularly zinc, influence substrate binding and catalytic activity of mammalian GGTase-I.
Isoprenoid donor binding and geranylgeranyl transfer
In simple terms: The enzyme then attaches a 20-carbon lipid tail to the cysteine.
The enzyme binds geranylgeranyl diphosphate (GGPP) and transfers the geranylgeranyl group to the thiol of the CaaX cysteine, forming a stable thioether linkage. This covalent modification increases the hydrophobicity of the substrate and promotes its interaction with membranes. The reaction is catalyzed by the heterodimeric GGTase-I complex, which contains a catalytic subunit and a regulatory subunit.
Metal ion dependence and catalytic mechanism
In simple terms: A zinc ion in the enzyme active site helps the chemistry happen.
Mammalian GGTase-I is a zinc metalloenzyme, and metal ions influence substrate binding and catalytic activity. The catalytic mechanism involves coordination of the zinc ion to the substrate cysteine thiol, facilitating nucleophilic attack on the geranylgeranyl diphosphate. This metal dependence distinguishes GGTase-I from some other prenyltransferases and has implications for inhibitor design.
Substrate specificity and downstream signaling
In simple terms: Once lipidated, the target protein can stick to membranes and send signals.
GGTase-I geranylgeranylates Rho-family GTPases including RHOA, RAC1 and CDC42, which require membrane anchoring for their signaling functions. Blocking this activity with inhibitors or genetic perturbation disrupts Rho-GTPase signaling and can inhibit tumor cell growth. Loss of GGTase-I function leads to unprenylated RHO GTPase signaling that activates the pyrin inflammasome and causes erosive arthritis.
Inhibitor binding and pharmacological modulation
In simple terms: Small molecules can block the enzyme and stop the lipid attachment.
Potent and selective GGTase-I inhibitors have been developed that compete with the isoprenoid donor or substrate and show cellular activity. Allenoate-derived compounds have been identified as inhibitors of both GGTase-I and Rab geranylgeranyltransferase, providing useful chemical probes. These inhibitors are valuable tools for studying the cellular consequences of blocking protein geranylgeranyltransferase activity.
Key Genes Involved in GO:0004661 protein geranylgeranyltransferase activity
The following genes encode the subunits, substrates and regulatory components most closely associated with protein geranylgeranyltransferase activity (GO:0004661).
| Gene | Major Role | Research Relevance |
|---|---|---|
| FNTA | Alpha subunit of GGTase-I and farnesyltransferase | Essential for enzyme complex assembly and catalytic activity |
| FNTB | Beta subunit of farnesyltransferase | Related prenyltransferase subunit; comparison with GGTase-I |
| PGGT1B | Beta subunit of GGTase-I | Catalytic subunit of GGTase-I; target for knockout and inhibitor studies |
| RABGGTA | Alpha subunit of Rab geranylgeranyltransferase | Distinguishes Rab GGTase from GGTase-I |
| RABGGTB | Beta subunit of Rab geranylgeranyltransferase | Rab GGTase catalytic subunit; inhibitor target |
| RHOA | Rho-family GTPase substrate of GGTase-I | Geranylgeranylation controls membrane localization and signaling |
| RAC1 | Rho-family GTPase substrate of GGTase-I | Prenylation required for cytoskeletal and inflammatory signaling |
| CDC42 | Rho-family GTPase substrate of GGTase-I | Prenylation regulates cell polarity and signaling |
| RHOB | Rho-family GTPase substrate | Geranylgeranylation affects trafficking and tumor suppression |
| RHOC | Rho-family GTPase substrate | Prenylation linked to cancer cell invasion |
| RHOJ | Rho-family GTPase substrate | Geranylgeranylation regulates endothelial and tumor biology |
| RND1 | Rho-family GTPase substrate | Prenylation-dependent membrane association |
| RND3 | Rho-family GTPase substrate | Geranylgeranylation influences cytoskeletal dynamics |
| RAP1A | Small GTPase substrate | Prenylation affects adhesion and signaling |
| RAP1B | Small GTPase substrate | Geranylgeranylation regulates integrin signaling |
| RAB1A | Rab GTPase substrate of Rab GGTase | Distinct prenylation pathway from GGTase-I |
| RAB5A | Rab GTPase substrate of Rab GGTase | Prenylation controls endosomal trafficking |
How Is protein geranylgeranyltransferase activity Regulated?
Protein geranylgeranyltransferase activity is regulated at multiple levels. The availability of the isoprenoid donor geranylgeranyl diphosphate, which is produced by the mevalonate pathway, directly influences the rate of geranylgeranylation. Metal ions, particularly zinc, modulate substrate binding and catalytic activity of mammalian GGTase-I. Pharmacological inhibitors can acutely block enzyme activity, and genetic loss of GGTase-I subunits alters downstream Rho-GTPase signaling. In the brain, GGTase-I-mediated prenylation is subject to developmental and activity-dependent regulation that affects neuronal function.
protein geranylgeranyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PGGT1B | Cancer; Rho-GTPase-driven proliferation | CRISPR knockout in cancer cell lines |
| RHOA | Cancer; cytoskeletal signaling | Point-mutation of CaaX cysteine to block prenylation |
| RAC1 | Autoinflammatory arthritis; pyrin inflammasome | Knock-in of unprenylated RAC1 variant |
| CDC42 | Cancer; cell polarity and invasion | Overexpression of wild-type and mutant CDC42 |
| FNTA | Cancer; prenyltransferase complex assembly | Knockout of FNTA to disrupt GGTase-I |
Cancer
Protein geranylgeranyltransferase type I has been extensively studied as a target in cancer because geranylgeranylation of Rho-family GTPases promotes proliferation, survival and invasion. Inhibitors of GGTase-I block Rho-GTPase signaling and show potent anti-tumor activity in phenotypic screens. Selective GGTase-I inhibitors with high potency and cellular activity have been developed as potential anticancer agents.
Autoinflammatory arthritis
Loss of GGTase-I function causes unprenylated RHO GTPase signaling that drives pyrin inflammasome activation and erosive arthritis in vivo. This links protein geranylgeranyltransferase activity directly to innate immune regulation and autoinflammatory disease pathogenesis.
Neurological and neurodegenerative disorders
Geranylgeranyltransferase I-mediated protein prenylation plays important roles in the brain, influencing neuronal survival, synaptic function and neurodegeneration-related pathways. Dysregulation of prenylation may contribute to neurological disease, making GGTase-I an emerging target for neurotherapeutic research.
From protein geranylgeranyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GGTase-I block Rho-GTPase membrane localization? | PGGT1B knockout cell line |
| Does a specific CaaX cysteine mutation prevent geranylgeranylation? | Point-mutation knock-in of RHOA CaaX cysteine |
| Can a disease-associated GGTase-I variant alter substrate specificity? | Knock-in of patient-derived PGGT1B mutation |
| Where does GGTase-I localize in cells? | Tagged knock-in of PGGT1B with fluorescent tag |
| Does GGTase-I overexpression enhance Rho-GTPase signaling? | Overexpression of PGGT1B and FNTA |
| Does GGTase-I inhibition activate the pyrin inflammasome? | Knockout or inhibitor-treated macrophage model |
How to Study the protein geranylgeranyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro prenylation assay | Transfer of geranylgeranyl group to substrate | Enzyme kinetics and inhibitor testing |
| Fluorescence microscopy | Membrane localization of prenylated proteins | Rho-GTPase trafficking studies |
| CRISPR knockout | Loss of GGTase-I subunit function | Causal testing of prenylation in cells |
| Point-mutation knock-in | Effect of specific CaaX cysteine mutation | Substrate specificity studies |
| Tagged knock-in | Subcellular localization of GGTase-I | Live-cell imaging |
| Overexpression | Gain-of-function of GGTase-I subunits | Signaling pathway activation |
| Inhibitor screening | Compound potency against GGTase-I | Drug discovery |
| Phenotypic screening | Anti-tumor activity via Rho-GTPase blockade | Cancer drug discovery |
Prenylation assays
In vitro prenylation assays using recombinant GGTase-I and substrate proteins measure the transfer of geranylgeranyl groups to CaaX-containing substrates. These assays can be used to test inhibitor potency and substrate specificity.
Membrane localization imaging
Fluorescence microscopy of tagged Rho GTPases in cells with GGTase-I knockout or inhibition reveals whether geranylgeranylation is required for membrane association. Tagged knock-in models allow direct visualization of GGTase-I localization.
CRISPR-based genetic perturbation
CRISPR knockout of PGGT1B or FNTA abolishes GGTase-I activity and enables downstream phenotypic analysis. Point-mutation and knock-in models can test the importance of specific residues in substrate or enzyme function.
Inhibitor screening and chemical biology
High-throughput screening of compound libraries identifies GGTase-I inhibitors with cellular activity. Allenoate-derived compounds have been used to probe both GGTase-I and Rab GGTase.
How CRISPR Can Be Used to Study GO:0004661 protein geranylgeranyltransferase activity
Knockout
CRISPR knockout of PGGT1B or FNTA eliminates GGTase-I activity and is used to test the requirement for geranylgeranylation in Rho-GTPase signaling, cell proliferation and inflammasome activation. Knockout models are also valuable for validating inhibitor specificity.
Point Mutation
Point-mutation knock-in of the CaaX cysteine in substrate GTPases such as RHOA prevents geranylgeranylation and allows researchers to separate prenylation-dependent from prenylation-independent functions. Point mutations in GGTase-I subunits can also be introduced to test catalytic residues.
Knock-in
Knock-in of tagged PGGT1B or disease-associated variants enables localization studies and functional analysis of GGTase-I in a physiological context. Knock-in models of unprenylated RHO GTPases can recapitulate autoinflammatory phenotypes.
Overexpression
Overexpression of GGTase-I subunits or substrate GTPases is used to enhance geranylgeranylation and study downstream signaling, including Rho-GTPase-driven proliferation and cytoskeletal changes.
How EDITGENE Supports protein geranylgeranyltransferase activity Research
Researchers studying protein geranylgeranyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in prenylation-dependent signaling, disease phenotypes or drug response. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable these investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for protein geranylgeranyltransferase activity research.
Frequently Asked Questions About protein geranylgeranyltransferase activity
What is protein geranylgeranyltransferase activity?
It is the enzymatic activity (GO:0004661) that covalently attaches a 20-carbon geranylgeranyl group to a cysteine residue near the C-terminus of a target protein via a thioether linkage.
What genes are involved in protein geranylgeranyltransferase activity?
Key genes include PGGT1B and FNTA, which encode GGTase-I subunits, as well as substrate GTPases such as RHOA, RAC1 and CDC42.
What is the difference between GGTase-I and Rab GGTase?
GGTase-I modifies CaaX-motif proteins such as Rho GTPases, while Rab GGTase modifies Rab proteins; both can be inhibited by allenoate-derived compounds.
How is protein geranylgeranyltransferase activity regulated?
It is regulated by geranylgeranyl diphosphate availability, metal ions such as zinc, and pharmacological inhibitors, and is influenced by developmental and activity-dependent signals in the brain.
What diseases are linked to protein geranylgeranyltransferase activity?
It has been linked to cancer, autoinflammatory erosive arthritis and neurological disorders.
Can CRISPR knockout be used to study GGTase-I?
Yes, CRISPR knockout of PGGT1B or FNTA is a standard approach to abolish GGTase-I activity and study downstream phenotypes.
What are common inhibitors of protein geranylgeranyltransferase activity?
Potent and selective GGTase-I inhibitors and allenoate-derived compounds have been developed and characterized.
Why is zinc important for GGTase-I activity?
Mammalian GGTase-I is a zinc metalloenzyme, and metal ions influence substrate binding and catalytic activity.
How does geranylgeranylation affect Rho GTPases?
Geranylgeranylation promotes membrane association of Rho GTPases, which is required for their signaling functions.
What experimental models are used to study protein geranylgeranyltransferase activity?
Common models include CRISPR knockout, point-mutation, knock-in and overexpression cell lines, as well as in vitro prenylation assays and inhibitor screens.
Conclusion
Protein geranylgeranyltransferase activity (GO:0004661) is a central post-translational modification mechanism that controls the membrane targeting and signaling of Rho-family GTPases and other CaaX-containing proteins. Its dysregulation is implicated in cancer, autoinflammatory arthritis and neurological disorders, and pharmacological inhibition has shown therapeutic potential in preclinical models. Continued research using CRISPR-based models and chemical probes will further clarify how this activity can be targeted in human disease.
References
- 1. Ullah N et al.. 2016. Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.. Curr Cancer Drug Targets 16(7):563-71 PMID: 26648485
- 2. Gao S et al.. 2016. The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the Brain.. Mol Neurobiol 53(10):6925-6937 PMID: 26666664
- 3. Marchwicka A et al.. 2022. Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization.. Int J Mol Sci 23(10) PMID: 35628237
- 4. Peterson YK et al.. 2006. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.. J Biol Chem 281(18):12445-50 PMID: 16517596
- 5. Watanabe M et al.. 2008. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds.. J Biol Chem 283(15):9571-9 PMID: 18230616
- 6. Akula MK et al.. 2025. Pyrin inflammasome-driven erosive arthritis caused by unprenylated RHO GTPase signaling.. EMBO Mol Med 17(10):2691-2712 PMID: 40883609
- 7. Zhang FL et al.. 1996. Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I.. Biochem J 320 ( Pt 3)(Pt 3):925-32 PMID: 9003382
- 8. Graham K et al.. 2024. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.. Cell Chem Biol 31(7):1247-1263.e16 PMID: 38537632
